AstraZeneca in pact with Quell Therapeutics for Treg cell therapies
Roland Magnusson/iStock Editorial via Getty Images

AstraZeneca (NASDAQ:AZN) and privately owned Quell Therapeutics announced a partnership on Friday to jointly develop T-regulator (Treg) cell therapies, the potential of which had previously attracted the likes of Bristol Myers Squibb (BMY) and Regeneron (REGN).
Per the terms, Quellâs Treg cell engineering modules will be used to develop autologous multi-modular Treg cell therapies for major autoimmune conditions such as Inflammatory Bowel Disease (IBD).

The British pharma giant will have an option to further advance and commercialize successful Treg candidates for Type 1 Diabetes (T1D) and IBD.
In return, Quell will receive $85M upfront in the form of cash and equity. The London-based biotech is also eligible for over $2B in development and commercial milestones in addition to tiered royalties.
In 2022, Bristol Myers Squibb (BMY) joined hands with GentiBio to develop Treg therapies for IBD. In March, Sonoma Biotherapeutics and Regeneron (REGN) partnered to focus on Treg therapies for autoimmune diseases.


More on AstraZeneca

AstraZeneca, Sanofi win FDA AdCom backing for RSV therapy nirsevimab
AstraZeneca: Think Medium-To-Long Term